View clinical trials related to Breast Cancer.Filter by:
Background: Some women with breast cancer and ovarian cancer are genetically predisposed to them. This is called hereditary breast and ovarian cancer (HBOC). The women have to make hard choices about tests and treatment. Researchers want to study the best way to guide them. A kind of writing exercise might help if it is done before genetic counseling. It is called a self-affirmation (SA) exercise. It may lead to better communication in the counseling and better behavioral outcomes. Objective: To test if an SA exercise done with HBOC genetic counseling could improve client communication and behavior. Eligibility: Adults ages 18 90 with an appointment at the HBOC clinic at St. Luke s Health System Adults ages 18 90 who are genetic counselors with breast and ovarian cancer clients Design: Appointment participants will be screened by phone. They will arrive 15 minutes early to their appointment. They will do a 10- to 15-minute survey and writing exercise. This includes questions about: If they have cancer If they have had or were offered genetic counseling Things that are important to them After the appointment, they will take a 10- to 15-minute follow-up survey. It can be in the office or online. It includes questions about how they felt about the writing exercise and their counseling. Counselor participants will take a 2- to 5-minute survey after sessions with clients in the study. This includes questions about how the client was in the session. They will take a 10- to 15-minute survey at the end of the study. It will be about their opinions of the writing exercise.
This a multicenter, open-label, phase II clinical trial to assess the efficacy of pembrolizumab in combination with eribulin in female patients older than 18 years old with hormone receptor-(HR)positive/HER2-negative metastatic breast cancer (MBC) previously treated with at least one, but not more than two, prior chemotherapeutic regimens for treatment of locally recurrent and/or metastatic disease. Prior therapy must have included an anthracycline and a taxane and prior anti-hormonal therapy is mandatory. The number of patients to be included is 44 patients at 11 sites. All eligible patients will be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle.
In this study, PLD, an anthracycline encapsulated in stealth liposomes, which are believed to efficiently deliver the doxorubicin within the tumour mass with less toxicity compared with standard doxorubicin formulation was used. The study aimed to determine whether the combination of PLD-docetaxel would increase tumour response in patients with breast cancer.
The significance of this study is that it will be the first prospective trial to compare MBI, a relatively low-cost functional breast imaging technique, to DBT, the new standard anatomic breast cancer screening technique in women with dense breasts. This study is also the first to evaluate two consecutive annual MBI scans to assess change in advanced cancer presentation after introduction of a functional imaging technique. These data will inform individualized decisions on supplemental screening and determine if a functional technique that is relatively low in cost and complexity of interpretation can eliminate the reservoir of clinically important breast cancers that remain occult on anatomic techniques. This study will also provide exploratory data about the optimal frequency of repeat MBI.
This is an exploratory interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for four weeks.
The goal of this study is to examine the role of Intraoperative Radiotherapy (IORT) in Ductal Carcinoma In-Situ (DCIS) and to improve the understanding of the clinical, radiographic, and patient-related impact of adopting IORT.
Radioisotopic and wire localizations suffer from several limitations. These techniques add another procedure prior to surgery, can be uncomfortable and entail additional cost. The aim is to develop a novel technique of breast tumor localization using preoperative magnetic resonance imaging (MRI) and breast optical scanning. Patients with diagnosis of breast cancer who have had a preoperative MRI and 3D optical scans are included. Optical scanning is done preoperatively and intraoperatively after tumor localization was marked on the breast using radioisotopic technique. The MRI is then adjusted with the intraoperative optical scan to match the breast position at the time of surgery. The investigators evaluate the efficiency for localization of breast lesion of the novel technique by comparison with radiosiotopic technique.
After neoadjuvant chemotherapy, patients normally receive either conservative breast surgery or mastectomy followed by radiation therapy. Some patients achieve a complete response after neoadjuvant chemotherapy. Considering that radiation therapy is an effective treatment for subclinical microscopic disease, the question arises whether breast surgery before radiation therapy can be avoided in the subgroup of patients with complete response after neoadjuvant chemotherapy.
PATH is a research study for cancer survivors to help participants to become more active. Studies suggested an association between inactivity and cancer. The investigators created new novel ways and technologies that may help participants to become more active. The three methods the investigators are studying are: 1) participant become active on her/his own; educational material will be provided; 2) working with a programmed health coach over the phone via text messages; and 3) using digital voice assist to help participant become more active. The digital voice assist will be delivered via Amazon Alexa on Echo speaker (it is the famous intelligent voice that you see in superball commercial by Alec Baldwin). This study is funded by the State of Maryland.
Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers